16 Aug 2022 , 11:03 AM
The company stated that Vasopressin Injection USP, 20 Units/mL Multiple-Dose Vials, are to be bioequivalent and therapeutically equivalent to the reference listed drug (RLD), Vasostrict Injection, 20 units/mL of Par Sterile Products, LLC (Par).
The company is planning to launch the product immediately.
As per the IQVIA data, the product has an estimated market size of around US$ 606 million for the twelve months ended June 2022.
This is the 146 ANDA (including ten tentative approvals) received by Eugia Pharma Speciality Group (EPSG) facilities, which manufacture both oral and sterile specialty products.
Vasopressin USP Injection is prescribed to treat Cardiovascular agent: vasoconstrictor. It is indicated to raise blood pressure in adults suffering from vasodilatory shock (for example, post-cardiotomy or sepsis).
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.